Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1632 of 5804
-
Could a malaria drug help fight recurrent bone cancer?
Disease control OngoingThis phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not respond to treatment. Drugs used in chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Which radiation dose is best for prostate cancer? new trial aims to find out
Disease control OngoingRadiation therapy is one of the standard treatments for men with prostate cancer. Moderately hypofractionated radiotherapy has been established to be equivalent to standard fractionated radiotherapy in several large randomized clinical trials, however different hypofractionated r…
Phase: NA • Sponsor: Tatarstan Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Blood test reveals why lung cancer drugs stop working
Knowledge-focused CompletedALK-positive lung cancer is a subtype of lung cancer which carries a change in a gene called ALK (anaplastic lymphoma kinase). There are now many drugs for patients with ALK-positive lung cancer that slow cancer growth. However, after some time, just as bacteria evolve resistance…
Sponsor: Addario Lung Cancer Medical Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can a drug holiday help women with rare uterine cancer?
Disease control Recruiting nowThe primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cocktail of three drugs shows promise for tough brain cancer
Disease control CompletedThe investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a simple steroid injection prevent a painful complication of esophageal surgery?
Prevention CompletedEndoscopic resection of superficial esophageal neoplasms is already a reality and presents important advantages when compared to esophagectomy as fewer complications and better quality of life. However, extensive resections can lead to difficult-to-manage stenoses. There are seve…
Phase: PHASE4 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
Double-Drug attack on lung cancer shows early promise
Disease control CompletedThe purpose of this study is to test the safety of dacomitinib and osimertinib, at increasing doses, to find out what effects, if any, this combination of drugs has on people with metastatic EGFR mutant lung cancer that has not been treated with an EGFR TKI.
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo tackles Tough-to-Treat colorectal cancer
Disease control CompletedA phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
New drug combo for transplant complication shows promise but study halted
Disease control TerminatedThe purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Phase: PHASE2, PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Fatty liver breakthrough? drug that boosts growth hormone shows promise
Disease control CompletedNonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolis…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail shows promise against Hard-to-Treat cancers
Disease control OngoingThis phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, e…
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may spot hidden sarcoma signals
Knowledge-focused Recruiting nowThis research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break dow…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a precise radiation burst stall Cancer's spread?
Disease control OngoingThe purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThe 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Magnetic brain zaps could lift depression in seniors without pills
Symptom relief CompletedMajor depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness, adverse effects and drug interactions, especially in the elderly population. In this context, the investigators invest…
Phase: NA • Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New dressing may keep amputation wounds clean and closed
Prevention CompletedThis study is a prospective, multi-center, two-arm, unblinded, and randomized controlled trial with a goal of evaluating the impact of a closed incision negative pressure dressing (PREVENA) on incidence of post-operative wound complications and medical costs in patients undergoin…
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
New genetic sleuthing could solve mysterious fetal swelling cases
Diagnosis CompletedBrief Summary: Nonimmune hydrops fetalis (NIHF) is a potentially fatal condition characterized by abnormal fluid accumulation in two or more fetal compartments. Numerous etiologies may lead to NIHF, and the underlying cause often remains unclear (1). The current standard of genet…
Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New MRI scan could predict kidney cancer aggressiveness without a biopsy
Diagnosis OngoingThis feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagn…
Phase: PHASE2 • Sponsor: Zhen Wang, MD • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
Blood test could steer cancer treatment to right drug
Disease control Recruiting nowThis multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating…
Phase: PHASE2 • Sponsor: Matteo's Friends • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacter…
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 18:33 UTC